Thermo Fisher Scientific Inc.

7 days ago · gurufocus.com

On October 26, 2026, we conducted a DCF analysis for Thermo Fisher Scientific Inc (TMO), a company currently trading at $673.82. The stock has shown a year-to-d

12 days ago · seekingalpha.com

Thermo Fisher Scientific Inc. delivered strong Q3 results, with 6% organic growth, EPS and sales beats, and raised full-year guidance. TMO's growth is driven by robust demand in clinical research, bioproduction, and electron microscopy, supported by recent strategic acquisitions. Operating margin reached 24.5%, aided by divestitures, acquisitions, and ongoing process improvements.

12 days ago · fool.com

Thermo Fisher raised its 2026 organic revenue growth outlook to 4%. Third-quarter revenue reached $12.14 billion with 6% organic growth.

12 days ago · gurufocus.com

Life-sciences tools giant Thermo Fisher Scientific (TMO) reported a strong third quarter Wednesday, with revenue up 9% and adjusted earnings per share up 15%. S

12 days ago · seekingalpha.com

Thermo Fisher Scientific Inc. (TMO) Q3 2026 Earnings Call Transcript

12 days ago · zacks.com

Thermo Fisher beats Q3 earnings and revenue estimates, with double-digit profit growth and wider margins, yet shares fall 4.1% in pre-market trading.

12 days ago · zacks.com

Although the revenue and EPS for Thermo Fisher (TMO) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

12 days ago · seekingalpha.com

Thermo Fisher Scientific Inc. delivered 6% organic growth, 120 bps margin expansion, and 39% free cash flow growth in Q3, validating the ongoing recovery. I maintain a Strong Buy rating on TMO, supported by accelerating earnings, improved profitability, and a declining net debt/EBITDA ratio (now 2.9x). Laboratory Products and Biopharma Services led with 10% organic growth, while Analytical Instruments posted 430 bps margin expansion, though Life Sciences and Diagnostics remain slower.

12 days ago · marketbeat.com

Thermo Fisher Scientific NYSE: TMO reported third-quarter revenue growth of 9% to $12.14 billion, supported by 6% organic growth, acquisitions and foreign-exchange effects. Adjusted earnings per share rose 15% to $6.68, while adjusted operating income increased 15% to $2.97 billion.

12 days ago · proactiveinvestors.com

Thermo Fisher Scientific Inc (NYSE:TMO, XETRA:TN8) increased third-quarter revenue by 9% to $12.14 billion, while adjusted earnings per share rose 15% to $6.68. Revenue for the three months ended September 2026 increased from $11.12 billion a year earlier, with organic revenue growth, which excludes the effects of acquisitions, disposals and currency movements, reaching 6%.